Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma. (20th December 2016)

• Record Type: Journal Article
• Authors: Ewers, Evan C.; Shah, Phalgoon A.; Carmichael, Mark G.; Ferguson, Tomas M.
• Is Part Of: Open forum infectious diseases. Volume 3:Number 4(2016)
• Publication Date: 2016-12-20
• Subjects: DLBCL -- Hepatitis C Virus -- Lymphoma -- Sofosbuvir; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofw223
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Hepatitis C virus (HCV) infection is associated with the development of non-Hodgkin lymphomas. For aggressive lymphomas, such as diffuse large B-cell lymphoma (DLBCL), treatment of HCV infection is typically deferred in treatment-naive patients until after completion of lymphoma therapy [1, 2] . We report a case of HCV-associated stage IV DLBCL successfully treated concurrently using chemoimmunotherapy and a sofosbuvir-based antiviral regimen.